Dynasil Corporation of America (DYSL)

[NoNameStocks]

another write up on DYSL, this time for the $2.49 tender

http://www.nonamestocks.com/2022/11/dysl-tender.html

[NoNameStocks]

another new write-up on DYSL

I wrote a follow up now that the company has sent out a report after de-registering.

DYSL's De-List is Working
http://www.nonamestocks.com/2021/02/dysls-de-list-is-working.html

[NoNameStocks]

new write up on DYSL

It's fallen too far following the SEC de-registration so I had to write about it on my blog:
http://www.nonamestocks.com/2019/09/catching-dysl-de-reg-drop.html

[Renee]

DYSL delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

[Enterprising Investor]

Dynasil Corporation of America Announces Results of Special Meeting of Stockholders; Company to Voluntarily Delist Common Stock From Nasdaq (8/07/19)

Dynasil Corporation of America (NASDAQ:DYSL) (the “Company”), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, industrial, medical, and biotech markets, today announced that at the Special Meeting of Stockholders held on August 7, 2019, the Company’s stockholders voted to approve proposals to amend the Company’s certificate of incorporation to effect a 1-for-8,000 reverse stock split of the Company’s common stock, followed immediately by an 8,000-for-1 forward stock split. The reverse and forward stock splits will be effected on August 7, 2019 and the Company’s common stock is expected to begin trading on The Nasdaq Stock Market on a post-forward stock split basis upon the opening of trading on August 8, 2019.

As a result of the reverse stock split, each share of the Company’s common stock held by a stockholder of record owning immediately prior to the effective time of the reverse stock split fewer than 8,000 shares of the Company’s common stock will be converted into the right to receive $1.15 in cash, without interest, and such stockholders will no longer be stockholders of the Company. To be entitled to such cash payment, a stockholder must be a record holder of fewer than 8,000 shares immediately prior to the effective time today of the reverse stock split. Investors who purchase fewer than 8,000 shares prior to the effective time today of the reverse stock split and settle such purchases after the effective time shall not be entitled to such cash payment and instead their trades will be settled on a post-forward stock split basis. Trades in the Company’s common stock made after Monday, August 5, 2019 will settle on a post-forward stock split basis.

Stockholders owning 8,000 or more shares of the Company’s common stock immediately prior to the effective time of the reverse stock split will not be entitled to receive any cash for their fractional share interests resulting from the reverse stock split, if any, and will instead remain stockholders in the Company holding, as a result of the forward stock split, the same number of shares of common stock as such stockholders held immediately before the effective time of the reverse stock split.

The Company has given notice to Nasdaq of its intent to voluntarily delist its common stock and to withdraw the registration of its common stock with the Securities and Exchange Commission (SEC). The Company intends to file a Form 25 Notification of Removal From Listing with the SEC on or about August 19, 2019. As a result, the Company expects that listing of its shares on Nasdaq will be terminated on or about August 29, 2019, at which time the Company intends to file a Form 15 with the SEC to suspend the Company’s reporting obligations under Section 15(d) of the Exchange Act. Following its delisting, the Company’s common stock may be quoted on the OTC Pink Open Market (the “Pink Sheets”), a centralized electronic quotation service for over-the-counter securities, if market makers demonstrate an interest in trading in the Company’s common stock. However, the Company can give no assurance that trading in its common stock will commence or continue on the Pink Sheets or any other securities exchange or quotation medium.

As previously announced, the Company is undertaking the deregistration and delisting transaction to avoid the substantial cost and expense of being a public reporting company and to allow the Company to focus on continued growth and enhancing long-term stockholder value. The Company anticipates savings exceeding $900,000 on an annual basis as a result of the proposed deregistration and delisting transaction.

For more information regarding the Company’s deregistration and delisting transaction, please refer to the definitive proxy statement on Schedule 14A filed with the SEC on June 25, 2019.

About Dynasil Corporation of America

Dynasil Corporation of America develops, markets, manufactures, and sells detection, sensing, and analysis technology and optical components in the United States, Europe, and internationally. It operates through three segments: Optics, Innovation and Development, and Biomedical. The Optics segment supplies synthetic crystals, optical materials, components, and coatings that are used in devices, such as baggage scanners, medical imaging systems, optical instruments, lasers, analytical instruments, automotive components, semiconductor/electronic devices, spacecraft/aircraft components, and advertising displays in the medical, industrial, and homeland security/defense sectors. The Innovation and Development segment develops advanced technology in materials, sensors, and prototype instruments that detect or measure radiation, light, magnetism, or sound for use in security, medical, and industrial applications. The Biomedical segment engages in the development of tissue sealant products. The Company distributes its products through direct sales and marketing staff, as well as through manufacturer's representatives and distributors. Dynasil Corporation of America was founded in 1960 and is headquartered in Newton, Massachusetts.

https://www.globenewswire.com/news-release/2019/08/07/1898560/0/en/Dynasil-Corporation-of-America-Announces-Results-of-Special-Meeting-of-Stockholders-Company-to-Voluntarily-Delist-Common-Stock-From-Nasdaq.html

[Enterprising Investor]

Proxy Statement (6/25/19)

https://www.sec.gov/Archives/edgar/data/30831/000114420419032287/tv521894-def14a.htm

[Enterprising Investor]

Christensen Capital, LLC beneficially owns of 977,311 shares (12/31/18)

Controls 5.6 percent.

https://www.sec.gov/Archives/edgar/data/30831/000178028819000002/ccsc13g062019.pdf

[Enterprising Investor]

Dynasil Corporation of America’s Board of Directors Approves Plan to Terminate Registration of Its Common Stock (5/02/19)

NEWTON, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Dynasil Corporation of America (Nasdaq:DYSL) today announced that a Special Committee of independent directors has recommended, and its Board of Directors has approved, a plan to cease the registration of the Company’s common stock under the federal securities laws following the completion of a proposed reverse stock split transaction and to delist its shares of common stock from trading on the Nasdaq Capital Market. It is expected that this plan would be effectuated in late summer 2019, subject to Dynasil’s stockholders approving the proposed reverse stock split at a Special Meeting of Stockholders to be held for that purpose, as described below.

Dynasil is taking these steps to avoid the substantial cost and expense of being a public reporting company and to focus the Company’s resources on enhancing long-term stockholder value. The Company anticipates savings exceeding $900,000 on an annual basis as a result of the proposed deregistration and delisting transaction.

The proposed reverse stock split is a 1-for-8,000 split, in which holders of less than 8,000 shares of the Company’s common stock would be cashed out at a price of $1.15 per share for their fractional shares. Such price represents a premium above the common stock’s closing price on May 1, 2019 and is supported by a fairness opinion by Mirus Capital Advisors Inc., whom the Special Committee engaged for such purpose. Stockholders owning 8,000 or more shares of the Company’s common stock prior to the reverse stock split would remain stockholders in Dynasil, which would no longer be encumbered by the expenses and distraction of a public reporting company. The number of shares they would own following the proposed transaction would be unchanged, as immediately after the reverse stock split a forward split of 8,000-for-1 would be applied to the continuing stockholders, negating any effects to them. Dynasil estimates that approximately 1.4 million shares (or less than 8% of the shares of its common stock currently outstanding) would be cashed out in the proposed transaction and the aggregate cost to the Company of the proposed transaction would be approximately $1.6 million, plus transaction expenses, which are estimated to be approximately $650,000. Dynasil intends to fund such costs using cash-on-hand and borrowings available under its existing credit facilities.

Dynasil’s Board of Directors has determined the proposed transaction is in the best interests of all of the Company’s stockholders. Dynasil currently realizes none of the traditional benefits of public company status, yet incurs all of the significant annual expenses and indirect costs associated with being a public company. Without its public company status, Dynasil would have an ongoing cost structure befitting its current and foreseeable scale of operations and its management would be able to have an increased focus on core operations. The purpose of the reverse stock split is to (i) help Dynasil stay below 300 record holders of its common stock, which is the level at which SEC public reporting obligations are required, (ii) offer liquidity to smaller stockholders at $1.15 per share without a brokerage commission and (iii) provide all stockholders the opportunity to vote on this matter. Among the factors considered by Dynasil’s Board of Directors were:

- the significant ongoing costs and management time and effort involved in the Company remaining a public company, including the preparation and filing of periodic and other reports with the SEC and compliance with Sarbanes-Oxley Act and other applicable requirements;

- the limited trading volume and liquidity of the Company’s common stock;

- the business and operations of the Company are expected to continue substantially as presently conducted, except without the burden of public company costs;

- enabling the Company’s stockholders with the smallest holdings, who represent a disproportionately large number of the record holders of Company’s common stock, to liquidate their holdings in the Company’s common stock and receive a premium over current market prices without incurring brokerage commissions;

- the determination of Mirus Capital Advisors Inc., independent fairness opinion provider to the Special Committee, that the transaction consideration for the fractional shares is fair from a financial point of view to the unaffiliated stockholders; and

- as a result of the deregistration and delisting, the ability of the Company’s management and employees to focus their time, effort and resources on the Company’s long-term growth and increasing long-term stockholder value.

Subject to regulatory clearance of the Company’s proxy statement to be filed relating to the proposed stock splits and stockholder approval thereof, it is anticipated that the proposed transaction would become effective shortly after the Special Meeting of Stockholders, which is expected to be held in the summer of 2019. Approval of the proposed transaction requires the affirmative vote of a majority of the shares cast (represented in person or by proxy) and entitled to vote at the Special Meeting. As of May 1, 2019, the Company’s directors and executive officers owned approximately 37% of the issued and outstanding shares of the Company’s common stock and are expected to vote “FOR” the transaction.

Promptly after the Special Meeting, the Company expects to terminate the registration of its common stock with the SEC and delist its common stock from the Nasdaq Capital Market. As a result, at such time, (i) the Company would cease to file annual, quarterly, current and other reports and documents with the SEC, and stockholders would cease to receive annual reports and proxy statements, and (ii) the Company’s common stock would no longer be listed on the Nasdaq Capital Market.
If consummated, the proposed stock splits would apply directly only to record holders of the Company’s common stock. Persons who hold shares of common stock in “street name” are encouraged to contact their bank, broker or other nominee for information on how the proposed transaction may affect any shares of the Company’s common stock held for their account.

The Board reserves the right to change the ratio of the reverse stock split to the extent it believes it is necessary or desirable in order to accomplish the Company’s goal of staying below 300 record holders. The Board may also abandon the proposed reverse stock split at any time prior to the completion of the proposed transaction if it believes the proposed transaction is no longer in the best interests of the Company or its stockholders.

Additional Information and Where to Find It

THIS PRESS RELEASE IS ONLY A BRIEF DESCRIPTION OF THE PROPOSED TRANSACTION. IT IS NOT A REQUEST FOR OR SOLICITATION OF A PROXY OR AN OFFER TO ACQUIRE OR SELL ANY SHARES OF COMMON STOCK. THE COMPANY INTENDS TO FILE A PROXY STATEMENT AND OTHER REQUIRED MATERIALS, INCLUDING A SCHEDULE 13E-3, WITH THE SEC CONCERNING THE PROPOSED STOCK SPLITS. A COPY OF ALL FINAL PROXY MATERIALS WILL BE SENT TO STOCKHOLDERS PRIOR TO A SPECIAL MEETING OF STOCKHOLDERS AT WHICH THE COMPANY’S STOCKHOLDERS WILL BE ASKED TO VOTE ON THE PROPOSALS DESCRIBED IN THE MATERIALS PROVIDED BY THE COMPANY. THE COMPANY URGES ALL STOCKHOLDERS TO READ THE PROXY STATEMENT WHEN IT BECOMES AVAILABLE, AS WELL AS ALL OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THOSE DOCUMENTS WILL INCLUDE IMPORTANT INFORMATION. A FREE COPY OF ALL MATERIALS THE COMPANY FILES WITH THE SEC, INCLUDING THE COMPANY’S SCHEDULE 13E-3 AND PROXY STATEMENT, WILL BE AVAILABLE AT NO COST ON THE SEC’S WEBSITE AT WWW.SEC.GOV. WHEN THOSE DOCUMENTS BECOME AVAILABLE, THE PROXY STATEMENT AND OTHER DOCUMENTS FILED BY THE COMPANY MAY ALSO BE OBTAINED WITHOUT CHARGE BY DIRECTING A REQUEST TO DYNASIL CORPORATION OF AMERICA, 313 WASHINGTON STREET, SUITE 403 NEWTON, MASSACHUSETTS 02458, ATTENTION: SECRETARY.

Dynasil and its directors and executive officers may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information concerning such participants is set forth in the proxy statement for Dynasil’s 2019 annual meeting of stockholders, which was filed with the SEC on Schedule 14A on January 10, 2019. To the extent that holdings of Dynasil’s securities have changed since the amounts printed in Dynasil’s proxy statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of such participants in the solicitation of proxies in connection with the proposed transaction will be included in the proxy statement to be filed by Dynasil with the SEC in connection with the proposed transaction.

About Dynasil Corporation of America

Dynasil Corporation of America develops, markets, manufactures, and sells detection, sensing, and analysis technology and optical components in the United States, Europe, and internationally. It operates through three segments: Optics, Innovation and Development, and Biomedical. The Optics segment supplies synthetic crystals, optical materials, components, and coatings that are used in devices, such as baggage scanners, medical imaging systems, optical instruments, lasers, analytical instruments, automotive components, semiconductor/electronic devices, spacecraft/aircraft components, and advertising displays in the medical, industrial, and homeland security/defense sectors. The Innovation and Development segment develops advanced technology in materials, sensors, and prototype instruments that detect or measure radiation, light, magnetism, or sound for use in security, medical, and industrial applications. The Biomedical segment engages in the development of tissue sealant products. The Company distributes its products through direct sales and marketing staff, as well as through manufacturer's representatives and distributors. Dynasil Corporation of America was founded in 1960 and is headquartered in Newton, Massachusetts.

https://www.globenewswire.com/news-release/2019/05/02/1815280/0/en/Dynasil-Corporation-of-America-s-Board-of-Directors-Approves-Plan-to-Terminate-Registration-of-Its-Common-Stock.html

[mexico1]

Someone likes it. CEO ..https://www.bamsec.com/filing/126041518000035?cik=30831

[MicroInvest77]

The CC transcript is out on Seeking Alpha. What a disaster. Excede a total loss, possible legal fees. I would not be surprised if some of the blood sucking lawyers file a class action lawsuit against Dynasil. How did Excede flip flop from the greatest money maker to a total disaster. Sounds like the blame was with salt water???!!

[MicroInvest77]

Xcede is a FLOP!!! So much for this blockbuster revenue generator!!! AMAZING!!!

[MicroInvest77]

I would wait until they release the quarterly earnings before buying. Haven't heard a word as to Xcede. RMD government orders are looking weak (see USAspending website. Optics may be the only bright spot.

[makinezmoney]

$DYSL: Looks Undervalued here at $1.47.... Possible BUYOUT

Reeling in almost $40Million in Annual Sales.

Pretty decent performance.

Company should be valued at no less than $8/sh


Taking a Position here.


https://www.dynasil.com//assets/DYSL-2018-Annual-Meeting-Management-Presentation-1.pdf





GO $DYSL

[MicroInvest77]

Why hasn't this company been sold yet?

[MicroInvest77]

Finally, there is life out there. This was good PR as it wasn't just a company PR puff piece, but was released from the Dept of Energy.

[Saskey]

Woo doggies! Shot right up there today! From a low of $1.28 to a high of $1.54, and it's only 10:15 a.m. That took my shares out, woo!

[MicroInvest77]

What is wrong with DYSL, the stock is stuck in the mud.

[WoollenBlock48]

Time to buy this up, golden cross forming

[Saskey]

3/1: Insider buying. 20,000 shares. Peter Sulick.

[Saskey]

I bought in at the perfect moment! Just looked at the chart and I bought in at the bottom of the down spike. Woo! I hadn't looked at what it's done since, so it's a Bigger Woo!

[Saskey]

Yup, loaded here too. You really thinking $1.60? Maybe I've got my sell point set too low!

[declaes]

Breaking 1.4$ will be the key

[jockinmikeg]

This chart is looking interesting again. As always, loading zone here has been $1.10-1.20. Looks ready for another shot up to $1.60.

[soupertrooper]

I’m more surprised that you’re surprised by this surprise.

[declaes]

Can you believe they give this news Ah? But going forward... thats ok.

[T1aris]

Get ready 2 booooom! 1.20s going 5x avg volume and news expected! Heads UP!!

[jockinmikeg]

This is a patience thing. Been here awhile too. Probably will get updates early 2018 on XCede. This isn’t a news-driven play so the grind is slow but it is undervalued.

[tradingjunk123]

I'm already loaded, been here a while. Tremendous value here and yes one day it will pop higher and continue.

[Titanium]

One day this stock will wake up. I'm loading

[declaes]

Well well... out to soon it seem. Happy about the profit after the long wait. You all longs enjoy. Bye

[declaes]

1,6 i'm out of here... glta

[declaes]

Wow, great stuf! This bod and mngm is a total joke. They proved it again wouldn't suprice me when this goes under 1$ soon.

[declaes]

News... why the F After hour? Com on!!!

[jockinmikeg]

Break and hold $1.30 and chart is poised to move much higher. Fundamentally and technically a buy.

[jockinmikeg]

A fellow DYSL investor did a write-up that he posted on ST. Lots of info,

https://docs.google.com/document/d/1C57NvHMEtWZDyCP4hA2qbkaWWwU6reT-b196nPTeMJQ/mobilebasic

[declaes]

Making money free to buy when this goes under 1$. Peter please

[declaes]

Under 1,2 seriously?

[declaes]

Hmmmm almost all trades at the ask today... 25000 shares. Hope it holds up this time. Still waiting for some news. Glta

[declaes]

8 trades and 60 shares traded... what a joke. Com'on.

[declaes]

Finaly a green day. Hope to move up from here again.

[jockinmikeg]

Most definitely. The market has priced XCede in as a failure because it's a cash burn and hasn't done much for years. If or when it gets some credible data released, I think it will go higher. Someone bought a lot of shares Monday.

[jockinmikeg]

Looks like an institutional buy this morning. This thing is just simmering before XCede preclinical news.

[declaes]

Is there news coming? Good volume and up 14%...

[declaes]

Hmmmm 100trade paint...

[tradingjunk123]

Mike, Patience, once clinical data starts coming out we will get noticed in a big way!

[jockinmikeg]

Long term play for sure, but XCede may bear fruit near-to mid term with positive preclinical data, which may spark some attention after weighing on the books dormant for so long.

[jockinmikeg]

I have been adding too. Positive preclinical trial news for XCede and I think this gets some attention, as it almost feels like failure is priced in since it sat on the shelf so long. They have credible partners for the biomedical and we should be hearing results this year. They have done a good job reducing debt, but revenues are lumpy. Optometrics growth should add a few cents per share over the next couple years.

[tradingjunk123]

Keep in mind Evarrest sold for over $400 million to J&J and Xcede works in less than half the time. Also, just remember we own our shares now long term, so when this takes off we pay less in capital gains. Cook Biotech I don't think would get involved if Xcede didn't look promising as well the CEO recently added over $400k bringing his investment to over $1 million alone in Xcede. Can be frustrating seeing DYSL at $1.30 but what will happen when it gets discovered or Xcede gets bought out? Patience. I want more shares

[declaes]

Hi TJ123, I know patience will pay just sad to see how the market works. DYSL is a stock to trade at 1.3 at this point. Much to come and waiting for dollars days, not 10 or 20 cent.

[tradingjunk123]

Patience patience. I think DYSL is worth more than $5+. Xcede is moving along and if comes to fruition DYSL is going to explode. When investors, institutions, day traders catch on this is going much higher and quickly